Published by World Health Organization (WHO) on Mar 16, 2021
This document is the update of an interim guidance originally published under the title “Clinical management of COVID-19: interim guidance, 27 May 2020".
WHO continues to monitor the situation closely for any changes that may affect this interim guidance. Should any factors change, WHO will issue a further update. Otherwise, this interim guidance document will expire 2 years after the date of publication.
© World Health Organization 2021. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence. WHO reference number: WHO/2019-nCoV/clinical/2021.1
World Health Organization (WHO)
Patients treated at home with confirmed or suspected COVID-19 disease
SpO2 < 92% (Pulse oximetry use at home)
SpO2 ≥ 92% (Pulse oximetry use at home)
Patients hospitalized with severe COVID-19 infection
Awake prone positioning + usual care
Hospitalized patients without an indication for therapeutic anticoagulation
Anticoagulation at therapeutic or intermediate intensity
Anticoagulation at prophylactic intensity
Patients with COVID-19 and ARDS or viral pneumonia who are critically ill in ICU, with or without invasive ventilation. Populations of children (defined <18 years) and adult patients (≥18 years)
Existing validated care bundles*, chosen locally by the hospital or ICU, adapted to local circumstances, and felt to be appropriate for patients with COVID-19 as specified above. *A care bundle is defined as three or more evidence informed practices delivered together and consistently to improve care.
Not using existing care bundles